67th ASH Annual Meeting & Exposition

Conference Coverage

Featured

Conference Coverage
Conference Coverage
12/09/2025
Kate Young
A phase 2 trial from the University of Miami evaluated whether combining iberdomide with carfilzomib, daratumumab, and dexamethasone could induce deep responses—including MRD-negativity—in patients with...
12/09/2025
Conference Coverage
Conference Coverage
12/08/2025
Anthony Calabro, MA
A randomized phase III study evaluated whether a carfilzomib-based triplet regimen could improve depth of response and progression-free survival compared with standard bortezomib-based therapy in patients...
12/08/2025
Conference Coverage
Conference Coverage
12/06/2025
Ashton L. Stahl
A new real-world study evaluates whether GLP-1 receptor agonists, commonly prescribed for diabetes and obesity, are associated with a reduced risk of progression from monoclonal gammopathy of undetermined...
12/06/2025

More

Conference Coverage
Conference Coverage
12/09/2025
Kate Young
A phase 2 trial from the University of Miami evaluated whether combining iberdomide with carfilzomib, daratumumab, and dexamethasone could induce deep responses—including MRD-negativity—in patients with...
12/09/2025
Conference Coverage
Conference Coverage
12/08/2025
Anthony Calabro, MA
A randomized phase III study evaluated whether a carfilzomib-based triplet regimen could improve depth of response and progression-free survival compared with standard bortezomib-based therapy in patients...
12/08/2025
Conference Coverage
Conference Coverage
12/06/2025
Ashton L. Stahl
A new real-world study evaluates whether GLP-1 receptor agonists, commonly prescribed for diabetes and obesity, are associated with a reduced risk of progression from monoclonal gammopathy of undetermined...
12/06/2025
Conference Coverage
Conference Coverage
12/06/2025
Ashton L. Stahl
In a multicenter US study of patients with relapsed/refractory multiple myeloma receiving commercial ciltacabtagene autoleucel, investigators examined whether rapid peak CAR T-cell expansion and absolute...
12/06/2025
Conference Coverage
Conference Coverage
12/10/2024
Anthony Calabro, MA
Researchers report on the first safety and efficacy of mosunetuzumab, a CD20xCD3 T-cell engaging bispecific antibody, for patients with relapsed/refractory Mantle cell lymphoma. This study was presented at...
12/10/2024